Aktis Oncology Announces Closing of Upsized Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares

Rhea-AI Summary

Aktis Oncology (NASDAQ: AKTS) closed an upsized initial public offering of 17,650,000 shares at $18.00 per share on January 12, 2026, and the underwriters fully exercised an option to purchase an additional 2,647,500 shares at the same price, with that sale expected to close on January 14, 2026, subject to customary conditions.

The aggregate gross proceeds including the overallotment are expected to be approximately $365.4 million before underwriting discounts, commissions and offering expenses. Aktis began trading on the Nasdaq Global Select Market on January 9, 2026 under the ticker AKTS.

Positive

• Gross proceeds of approximately $365.4 million
• Underwriters fully exercised 2,647,500-share overallotment
• Common stock began trading on Nasdaq Global Select Market under AKTS

Negative

• Gross proceeds are before underwriting discounts, commissions and offering expenses, which will reduce net proceeds

News Market Reaction

-1.84%

5 alerts

-1.84% News Effect

-19.1% Trough in 25 hr 2 min

-$21M Valuation Impact

$1.14B Market Cap

0.0x Rel. Volume

On the day this news was published, AKTS declined 1.84%, reflecting a mild negative market reaction. Argus tracked a trough of -19.1% from its starting point during tracking. Our momentum scanner triggered 5 alerts that day, indicating moderate trading interest and price volatility. This price movement removed approximately $21M from the company's valuation, bringing the market cap to $1.14B at that time.

Data tracked by StockTitan Argus on the day of publication.

Key Figures

IPO primary shares: 17,650,000 shares IPO price: $18.00 per share Underwriters’ option shares: 2,647,500 shares +5 more

8 metrics

IPO primary shares 17,650,000 shares Initial public offering common stock

IPO price $18.00 per share Initial public offering price

Underwriters’ option shares 2,647,500 shares Additional shares under option at IPO price

Gross proceeds $365.4 million Aggregate gross proceeds before expenses

Form S-1 file number 333-292283 SEC registration statement for offering

Trading start date January 9, 2026 Nasdaq Global Select Market listing for AKTS

Effectiveness date January 8, 2026 SEC effectiveness of Form S-1

Option closing date January 14, 2026 Expected closing of additional share sale

Market Reality Check

Price: $20.25 Vol: Volume 828,271 vs 20-day ...

low vol

$20.25 Last Close

Volume Volume 828,271 vs 20-day average 28,368,642, indicating unusually light trading. low

Technical Price 21.75 trading above 200-day MA at 0.44.

Historical Context

1 past event · Latest: Jan 09 (Positive)

Pattern 1 events

Date	Event	Sentiment	Move	Catalyst
Jan 09	IPO milestone	Positive	+60115.1%	IPO capital raise and highlighting pipeline and Lilly collaboration.

Pattern Detected

Limited history, but the prior IPO-related news showed a strong positive alignment between announcement and price reaction.

Recent Company History

Over the recent period, Aktis Oncology’s key milestone was entering the public markets. On Jan 9, 2026, an IPO-related announcement highlighted a capital raise of $318 million, substantial prior private funding of about $346 million, and a collaboration with Eli Lilly valued up to $1.2 billion. The stock reacted strongly, with a 60115.1% move, indicating outsized sensitivity to capital markets and partnership news compared with typical trading behavior.

Market Pulse Summary

This announcement confirms the closing of Aktis Oncology’s upsized IPO and full exercise of the unde...

Analysis

This announcement confirms the closing of Aktis Oncology’s upsized IPO and full exercise of the underwriters’ option, resulting in expected gross proceeds of about $365.4 million. It follows earlier communications about a significant capital raise and strategic collaborations. Investors monitoring this development may focus on how the new capital supports clinical progress, future regulatory milestones, and the company’s ability to translate its radiopharmaceutical pipeline into durable operational and financial execution.

Key Terms

initial public offering, underwriters’ option, Nasdaq Global Select Market, registration statement on Form S-1, +1 more

5 terms

initial public offering financial

"announced the closing of its upsized initial public offering of 17,650,000 shares"

An initial public offering (IPO) is when a private company first sells its shares to the public and becomes a stock-listed company. It matters because it allows the company to raise money from a wide range of investors, helping it grow, while giving early shareholders a way to sell some of their ownership.

underwriters’ option financial

"underwriters exercised in full their option to purchase an additional 2,647,500 shares"

An underwriters’ option is a provision in a securities offering that lets the group selling the new shares buy a fixed extra amount (often up to 15%) from the issuer after the sale. It acts like a short-term safety valve: if demand is strong, underwriters exercise the option and supply extra shares; if the price falls, they can use the option to stabilize the market. For investors this matters because it affects how many shares come to market, potential short-term dilution, and post-offering price stability—similar to having a reserve supply to smooth out sudden swings.

Nasdaq Global Select Market financial

"common stock began trading on the Nasdaq Global Select Market on January 9, 2026"

A Nasdaq Global Select Market listing is the highest tier of stocks on the Nasdaq exchange, reserved for companies that meet the strictest financial, reporting and governance standards. For investors, it acts like a premium quality label—signaling larger, more transparent and better-governed companies that tend to offer greater liquidity and lower perceived risk compared with lower-tier listings, making it easier to buy, sell and evaluate shares.

registration statement on Form S-1 regulatory

"A registration statement on Form S-1 (File No. 333-292283), as amended, relating to the offering"

A registration statement on Form S-1 is a detailed filing a company submits to the U.S. securities regulator to register new shares for public sale; it includes a plain-language prospectus, financial statements, business description and risk factors. For investors it matters because it provides the official, comprehensive blueprint of the offering — like an owner’s manual — allowing buyers to assess risks, inspect financial health and compare valuation before deciding to invest.

prospectus regulatory

"The offering was made only by means of a prospectus."

A prospectus is a detailed document that explains a company's plans for offering new shares or investments to the public. It’s important because it provides potential investors with key information about the company’s business, risks, and how they might make money, helping them decide whether to invest. Think of it as a guidebook for understanding what you're buying into.

AI-generated analysis. Not financial advice.

BOSTON, Jan. 13, 2026 (GLOBE NEWSWIRE) -- Aktis Oncology, Inc. (“Aktis”), a clinical-stage oncology company focused on expanding the breakthrough potential of targeted radiopharmaceuticals to large patient populations, including those not addressed by existing platform technologies, today announced the closing of its upsized initial public offering of 17,650,000 shares of its common stock, at an initial public offering price of $18.00 per share, occurred on January 12, 2026. In addition, the underwriters exercised in full their option to purchase an additional 2,647,500 shares of Aktis’ common stock, at the initial public offering price of $18.00 per share. The sale of the 2,647,500 additional shares is expected to close on January 14, 2026, subject to satisfaction of customary closing conditions. The aggregate gross proceeds from the initial public offering, including the full exercise of the underwriters’ option to purchase additional shares, before deducting underwriting discounts and commissions and other offering expenses, are expected to be approximately $365.4 million. All of the shares of common stock were offered by Aktis. Aktis’ common stock began trading on the Nasdaq Global Select Market on January 9, 2026 under the ticker symbol “AKTS.”

J.P. Morgan, BofA Securities, Leerink Partners and TD Cowen acted as joint book-running managers for the offering.

A registration statement on Form S-1 (File No. 333-292283), as amended, relating to the offering has been filed with the Securities and Exchange Commission (the “SEC”) and was declared effective on January 8, 2026. The offering was made only by means of a prospectus. Copies of the final prospectus relating to the offering may be obtained through the SEC’s website at www.sec.gov. Alternatively, copies of the final prospectus relating to the offering may be obtained from: J.P. Morgan Securities LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, New York 11717 or by email at prospectus-eq_fi@jpmchase.com and postsalemanualrequests@broadridge.com; BofA Securities, NC1-022-02-25, 201 North Tryon Street, Charlotte, North Carolina 28255-0001, Attention: Prospectus Department, or by email at dg.prospectus_requests@bofa.com; Leerink Partners LLC, Attention: Syndicate Department, 53 State Street, 40th Floor, Boston, MA 02109, by telephone at (800) 808-7525 ext. 6105, or by email at syndicate@leerink.com; or TD Securities (USA) LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, New York 11717 or by email at TDManualrequest@broadridge.com.

This press release does not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

About Aktis Oncology

Aktis Oncology, Inc. is a clinical-stage oncology company focused on expanding the breakthrough potential of targeted radiopharmaceuticals to large patient populations, including those not addressed by existing platform technologies. Aktis’ most advanced pipeline program targets Nectin-4, a miniprotein radioconjugate with multi-indication potential across multiple tumor types. Founded and incubated by MPM BioImpact, Aktis has developed its proprietary miniprotein radioconjugate platform to selectively deliver the tumor-killing properties of radioisotopes to targeted tumors. Designed to maximize tumor killing through high penetration followed by internalization and retention in cancer cells, Aktis’ miniprotein radioconjugates are designed to quickly clear from normal organs and tissues, thereby maximizing anticancer activity while minimizing side effects of treatment. The Aktis platform is isotope-agnostic and further enables clinicians to visualize and verify target engagement with imaging isotopes prior to exposure to therapeutic radioisotopes. Aktis also has a strategic collaboration with Eli Lilly and Company to leverage its miniprotein platform to develop novel radioconjugates outside of Aktis’ proprietary pipeline.

Media Contact:
Sean Leous
ICR Healthcare
(646) 866-4012
Sean.Leous@icrhealthcare.com

Investor Contact:
Peter Vozzo 
ICR Healthcare
(443) 213-0505
Peter.Vozzo@icrhealthcare.com

FAQ

How many shares did Aktis Oncology sell in its upsized IPO (AKTS) and at what price?

Aktis sold 17,650,000 shares at $18.00 per share, plus a 2,647,500-share overallotment at the same price.

What are the total gross proceeds from the Aktis Oncology IPO (AKTS)?

Aggregate gross proceeds including the full overallotment are expected to be approximately $365.4 million before fees and expenses.

When did AKTS begin trading on Nasdaq and what is the ticker?

Aktis common stock began trading on the Nasdaq Global Select Market on January 9, 2026 under ticker AKTS.

When will the additional 2,647,500 overallotment shares for AKTS close?

The sale of the additional 2,647,500 shares is expected to close on January 14, 2026, subject to customary closing conditions.

Where can investors obtain the Aktis Oncology IPO prospectus for AKTS?

Copies of the final prospectus are available via the SEC website at www.sec.gov or from the offering managers named in the prospectus.

Did Aktis offer shares from existing holders or directly from the company in the AKTS IPO?

All of the shares were offered by Aktis (the company) rather than by selling stockholders.